Abstracts

19 – Cellular and Tissue Sources of Viral Persistence and Rebound

Cellular and tissue sources of viral rebound primarily originate from long-lived reservoirs of HIV in individuals under antiretroviral therapy (ART). Key cellular reservoirs include CD4+ T cells, particularly memory subsets like central memory (Tcm), which harbor latent provirus. Tissue-specific sources include lymphoid tissues (lymph nodes, spleen, and gut-associated lymphoid tissue), where virus can persist despite…

47 – Dolutegravir Resistance: What Are the Implications for Antiretroviral Therapy Programs?

Introduction DTG-based regimens have simplified management for providers: Resistance to 1st-line DTG-based regimens is still incredibly rare. Therefore limited role for resistance testing in this scenario; can mostly assume non-adherence if viral load elevated. Fewer resistance tests required; less unnecessary switching drug classes, esp. in LMIC.  “Blind” switching to DTG-based regimens without requiring a resistance…

45 – Emerging Role of T Cells in the Central Nervous System

This presentation will address how T cell and specific T cell subsets are revealing new insights in neuroHIV pathogenesis, specifically in HIV neuroinvasion, persistence, and neuroprotection. Recent data will show the establishment and maintenance of infected CD4 T cells in the brain from acute infection to ART-suppression, discuss the role of CD8 T cells in…

30 – How HIV Integrates Into the Genome

The HIV Preintegration Complex (PIC) mediates the integration of the viral reverse transcript into host cell chromosomes. The HIV core is composed of a shell of capsid protein that encases the viral RNA together with reverse transcriptase and integrase enzymes. Reverse transcription occurs within the viral core, and nicking of the viral DNA ends by…

49 – Leveraging Private-Sector Pharmacies to Expand Reach of Biomedical HIV Prevention Interventions

Private-sector pharmacies are ubiquitous in many African countries yet underutilized for delivery of HIV prevention services, including pre- and post-exposure prophylaxis (PrEP and PEP). This is a missed opportunity, as pharmacies are staffed by medical professionals (e.g., pharmacists, pharmaceutical technologists); are frequently accessed for sexual and reproductive health products (e.g., contraception, treatment for sexually transmitted…

36 – Long-Acting Treatments for Tuberculosis

Long-acting injectable formulations are revolutionizing HIV treatment and prevention and have similar potential to improve the treatment and prevention of tuberculosis, including simpler, shorter regimens and expanded treatment options. This presentation will describe how long-acting injectable formulations could address important obstacles to ending the world’s oldest pandemic, review recent progress in the development of long-acting…